Tenofovir as a first line option for prophylaxis in a patient with hepatitis B virus associated nephrotic syndrome
Journal Title: Annals of Hepatology - Year 2011, Vol 10, Issue 3
Abstract
Authors and Affiliations
Seyfettin Köklü, Selman Unverdi, Mevlut Ceri, Hatice Unverdi, Erdem Koçak, Murat Duranay
Keywords
Related Articles
- EP ID EP78058
- DOI -
- Views 109
- Downloads 0
The prevalence of nonalcoholic fatty liver disease in the Americas
Nonalcoholic fatty liver disease (NAFLD) is an alarming public health problem. The disease is one of the main causes of chronic liver disease worldwide and is directly linked to the increased prevalence of obesity and ty...
Analysis of hepatitis C virus (HCV) RNA load in platelets of HCV-monoinfected patients receiving antiviral therapy
[b]Introduction[/b]. Detection of hepatitis C virus (HCV) has been reported in extrahepatic sites such as peripheral blood mononuclear cells and platelets. Quantitation of HCV-RNA in platelets from patients under antivir...
Acute liver failure associated with Garcinia cambogia use
Millions of Americans regularly use herbal supplements, but many are unaware of the potential hidden dangers. Numerous supplements have been associated with hepatotoxicity and, indeed dietary/herbal supplements represent...
Liver involvement in severe humann influenza A H1N1
Influenza A is a disease caused by a RNA virus, member of the orthomyxoviridae family. The influenza infection is characterized primarily by pulmonary affection that may advance to an acute pulmonary respiratory failure...
Treatment of chronic hepatitis C genotype 1 early responders with 36 week pegylated interferon and ribavirin therapy
Introduction. Standard treatment for patients with chronic hepatitis C genotype 1 (CHC G-1) infection includes pegylated interferon plus ribavirin (PEG-RBV) for 48 weeks. Shorter treatment regimen would be more acceptabl...